Validating a composite endpoint for acceptability evaluation of oral drug formulations in the pediatric population: a...

Area of Science:

• Pharmacology and Pharmaceutical Sciences
• Pediatric Drug Development
• Clinical Trial Methodology

Background:

• Assessing the acceptability of oral pediatric drug formulations is crucial for adherence and therapeutic success.
• Existing methods may not fully capture the complex factors influencing children's acceptance of medications.
• Swallowability and palatability are key determinants of medication acceptability in pediatric populations.

Purpose of the Study:

• To validate a newly developed composite acceptability endpoint for oral pediatric drug formulations.
• To integrate swallowability and palatability assessments into a unified measure of drug acceptability.
• To evaluate the sensitivity of this composite endpoint across different pediatric age groups and formulations.

Main Methods:

• An open-label study was conducted with 320 children across three age groups: 1-<6 months, 6-<12 years, and 12-<18 years.
• A 2-way cross-over design was used for the youngest group (syrup and mini-tablets).
• An incomplete block design with four sequences evaluated syrup, mini-tablets, oblong tablets, and round tablets in older children (6-<18 years).

Main Results:

• The composite acceptability endpoint demonstrated age-specific differences in formulation acceptance.
• Mini-tablets were most acceptable for children aged 1-<6 months and 6-<12 years.
• Adolescents (12-<18 years) showed a preference for the oblong tablet formulation.

Conclusions:

• The composite acceptability endpoint, integrating swallowability and palatability, is a sensitive tool for assessing pediatric drug acceptability.
• This validated endpoint can effectively differentiate between formulations based on age-specific preferences.
• The findings support the use of this comprehensive endpoint in pediatric drug development and formulation design.